Laroprovstat vs Recaticimab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atherosclerotic Cardiovascular Disease

Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline

Laroprovstat

Developed by AstraZeneca

Phase 3 in Atherosclerotic Cardiovascular Diseasesmall molecule
Reliable signal

NCT06173570 · Phase 2 · completed

The study randomized 428 participants to four AZD0780 dose groups or matched placebo and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary endpoint was the regulator-accepted lipid measure LDL cholesterol, and all four AZD0780-versus-placebo comparisons were statistically significant in the favorable direction (p<0.001).

Next expected readout: January 2027 · NCT07000136 (registry estimate)

Reported efficacy

Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline to Week 12 (From first day of treatment up to week 12): Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline to Week 12 (From first day of treatment up to week 12): AZD0780 1 mg -31.19% (95% CI -37.06--25.32) vs AZD0780 3 mg -33.83% (95% CI -39.78--27.88) vs AZD0780 10 mg -41.09% (95% CI -46.92--35.25) vs AZD0780 30 mg -46.62% (95% CI -52.48--40.76) vs Placebo 4.08% (95% CI -1.84-10.00); p=< 0.001 (AZD0780 1 mg vs Placebo), p=< 0.001 (AZD0780 3 mg vs Placebo), p=< 0.001 (AZD0780 10 mg vs Placebo), p=< 0.001 (AZD0780 30 mg vs Placebo) (met)

Result source: NCT06173570

Recaticimab

Marketed by Jiangsu Hengrui Pharmaceuticals

Phase 3 in Atherosclerotic Cardiovascular Diseasemonoclonal antibody
Reliable signal

NCT04849000 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial with 709 participants, using percentage change in LDL cholesterol as the primary measure. The sponsor reports statistically significant LDL reductions of 45 to 53 percentage points versus placebo across all three dosing regimens.

Next expected readout: June 2027 · NCT07373847 (registry estimate)

Reported efficacy

12 weeks Percentage change in serum LDL-C levels from baseline.: Change in LDL-C from baseline at Week 12: -54.4% recaticimab vs -4.5% placebo; treatment difference -49.8 percentage points (95% CI -55.8 to -43.9), P<0.0001 (met)

Result source: NCT04844125

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLaroprovstatRecaticimab
LDL-C, % change-46.6% vs 4.1%−50.7 vs placebo30 mg · wk 12 · n 85NCT06173570
7 other results
  • -41.1% vs 4.1% 10 mg · wk 12 · n 84 · Phase 2 · primary NCT06173570
  • -33.8% vs 4.1% 3 mg · wk 12 · n 85 · Phase 2 · primary NCT06173570
  • -31.2% vs 4.1% 1 mg · wk 12 · n 86 · Phase 2 · primary NCT06173570
  • -46.4% vs 3.4% 30 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -40.5% vs 3.4% 10 mg · wk 12 · n 84 · Phase 2 · secondary NCT06173570
  • -33.4% vs 3.4% 3 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -30.5% vs 3.4% 1 mg · wk 12 · n 86 · Phase 2 · secondary NCT06173570
-51% vs 2%a−53 vs placebo450mg Q12W · wk 24NCT04885218
3 other results
  • -59% vs 0.4% 300mg Q8W · wk 24 · Phase 3 · primary NCT04885218
  • -62% vs 0% 150mg Q4W · wk 24 · Phase 3 · primary NCT04885218
  • -54.4% vs -4.5% wk 12 · Phase 3 · primary NCT04844125
Non-HDL-C, % change-41.6% vs 3.5%−45.2 vs placebo30 mg · wk 12 · n 85NCT06173570
7 other results
  • -41.4% vs 2.9% 30 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -35.1% vs 3.5% 10 mg · wk 12 · n 84 · Phase 2 · secondary NCT06173570
  • -34.8% vs 2.9% 10 mg · wk 12 · n 84 · Phase 2 · secondary NCT06173570
  • -29.9% vs 3.5% 3 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -29.4% vs 2.9% 3 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -26.9% vs 3.5% 1 mg · wk 12 · n 86 · Phase 2 · secondary NCT06173570
  • -26.1% vs 2.9% 1 mg · wk 12 · n 86 · Phase 2 · secondary NCT06173570
—Not posted · NCT04844125
ApoB, % change-37.0% vs 2.9%−39.9 vs placebo30 mg · wk 12 · n 85NCT06173570
7 other results
  • -36.9% vs 2.4% 30 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -34.3% vs 2.9% 10 mg · wk 12 · n 84 · Phase 2 · secondary NCT06173570
  • -33.9% vs 2.4% 10 mg · wk 12 · n 84 · Phase 2 · secondary NCT06173570
  • -25.4% vs 2.9% 3 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -24.5% vs 2.4% 3 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -24.1% vs 2.9% 1 mg · wk 12 · n 86 · Phase 2 · secondary NCT06173570
  • -23.4% vs 2.4% 1 mg · wk 12 · n 86 · Phase 2 · secondary NCT06173570
—Not posted · NCT04844125
Lp(a), % change-19.4% vs 0%−19.4 vs placebo30 mg · wk 12 · n 76NCT06173570
3 other results
  • -19.6% vs 0% 10 mg · wk 12 · n 81 · Phase 2 · secondary NCT06173570
  • -11.2% vs 0% 3 mg · wk 12 · n 75 · Phase 2 · secondary NCT06173570
  • -7.5% vs 0% 1 mg · wk 12 · n 75 · Phase 2 · secondary NCT06173570
—Not posted · NCT04844125
3-point MACE (% with event)—Trial running · NCT06834932—Not posted · NCT04844125

LDL-C, % change

Laroprovstat
-46.6% vs 4.1%−50.7 vs placebo30 mg · wk 12 · n 85NCT06173570
7 other results
  • -41.1% vs 4.1% 10 mg · wk 12 · n 84 · Phase 2 · primary NCT06173570
  • -33.8% vs 4.1% 3 mg · wk 12 · n 85 · Phase 2 · primary NCT06173570
  • -31.2% vs 4.1% 1 mg · wk 12 · n 86 · Phase 2 · primary NCT06173570
  • -46.4% vs 3.4% 30 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -40.5% vs 3.4% 10 mg · wk 12 · n 84 · Phase 2 · secondary NCT06173570
  • -33.4% vs 3.4% 3 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -30.5% vs 3.4% 1 mg · wk 12 · n 86 · Phase 2 · secondary NCT06173570
Recaticimab
-51% vs 2%a−53 vs placebo450mg Q12W · wk 24NCT04885218
3 other results
  • -59% vs 0.4% 300mg Q8W · wk 24 · Phase 3 · primary NCT04885218
  • -62% vs 0% 150mg Q4W · wk 24 · Phase 3 · primary NCT04885218
  • -54.4% vs -4.5% wk 12 · Phase 3 · primary NCT04844125

Non-HDL-C, % change

Laroprovstat
-41.6% vs 3.5%−45.2 vs placebo30 mg · wk 12 · n 85NCT06173570
7 other results
  • -41.4% vs 2.9% 30 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -35.1% vs 3.5% 10 mg · wk 12 · n 84 · Phase 2 · secondary NCT06173570
  • -34.8% vs 2.9% 10 mg · wk 12 · n 84 · Phase 2 · secondary NCT06173570
  • -29.9% vs 3.5% 3 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -29.4% vs 2.9% 3 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -26.9% vs 3.5% 1 mg · wk 12 · n 86 · Phase 2 · secondary NCT06173570
  • -26.1% vs 2.9% 1 mg · wk 12 · n 86 · Phase 2 · secondary NCT06173570
Recaticimab
—Not posted · NCT04844125

ApoB, % change

Laroprovstat
-37.0% vs 2.9%−39.9 vs placebo30 mg · wk 12 · n 85NCT06173570
7 other results
  • -36.9% vs 2.4% 30 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -34.3% vs 2.9% 10 mg · wk 12 · n 84 · Phase 2 · secondary NCT06173570
  • -33.9% vs 2.4% 10 mg · wk 12 · n 84 · Phase 2 · secondary NCT06173570
  • -25.4% vs 2.9% 3 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -24.5% vs 2.4% 3 mg · wk 12 · n 85 · Phase 2 · secondary NCT06173570
  • -24.1% vs 2.9% 1 mg · wk 12 · n 86 · Phase 2 · secondary NCT06173570
  • -23.4% vs 2.4% 1 mg · wk 12 · n 86 · Phase 2 · secondary NCT06173570
Recaticimab
—Not posted · NCT04844125

Lp(a), % change

Laroprovstat
-19.4% vs 0%−19.4 vs placebo30 mg · wk 12 · n 76NCT06173570
3 other results
  • -19.6% vs 0% 10 mg · wk 12 · n 81 · Phase 2 · secondary NCT06173570
  • -11.2% vs 0% 3 mg · wk 12 · n 75 · Phase 2 · secondary NCT06173570
  • -7.5% vs 0% 1 mg · wk 12 · n 75 · Phase 2 · secondary NCT06173570
Recaticimab
—Not posted · NCT04844125

3-point MACE (% with event)

Laroprovstat
—Trial running · NCT06834932
Recaticimab
—Not posted · NCT04844125
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Laroprovstat: 4 of 4 rows · Recaticimab: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLaroprovstatRecaticimab
Dropout rate
5.9%30 mga
NCT06173570 · Phase 2
show 3 more results
1.2%10 mg
NCT06173570 · Phase 2
4.7%3 mg
NCT06173570 · Phase 2
5.8%1 mg
NCT06173570 · Phase 2
—
Discontinued due to AEs
2.4%30 mga
NCT06173570 · Phase 2
show 3 more results
0%10 mg
NCT06173570 · Phase 2
0%3 mg
NCT06173570 · Phase 2
1.2%1 mg
NCT06173570 · Phase 2
—
Serious AEs
1.2%30 mga
NCT06173570 · Phase 2
show 3 more results
2.4%10 mg
NCT06173570 · Phase 2
2.4%3 mg
NCT06173570 · Phase 2
2.3%1 mg
NCT06173570 · Phase 2
—
Most frequent reported AEs
30 mga
hypertension 3.5% (placebo 5.8%)
NCT06173570 · Phase 2
show 3 more results
10 mg
hypertension 2.4% (placebo 5.8%)
NCT06173570 · Phase 2
3 mg
hypertension 2.4% (placebo 5.8%)
NCT06173570 · Phase 2
1 mg
hypertension 4.7% (placebo 5.8%)
NCT06173570 · Phase 2
—

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Laroprovstat

Total Cholesterol -27.06% (n=85) vs 2.29% (n=86) placebo @ 12wk30 mg
percent change · % of baseline
NCT06173570 · Phase 2
show 7 more results
-26.9% (n=85) vs 1.73% (n=86) placebo @ 12wk30 mg
NCT06173570 · Phase 2
-24.84% (n=84) vs 2.29% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
-24.54% (n=84) vs 1.73% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
-20.09% (n=85) vs 2.29% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
-19.8% (n=85) vs 1.73% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
-18.93% (n=86) vs 2.29% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
-18.23% (n=86) vs 1.73% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
HDL-C 4.66% (n=85) vs 3.65% (n=86) placebo @ 12wk30 mg
percent change · % of baseline
NCT06173570 · Phase 2
show 7 more results
4.65% (n=85) vs 3.11% (n=86) placebo @ 12wk30 mg
NCT06173570 · Phase 2
1.97% (n=84) vs 3.65% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
2.17% (n=84) vs 3.11% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
4.03% (n=85) vs 3.65% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
3.66% (n=85) vs 3.11% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
0.12% (n=86) vs 3.65% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
0.8% (n=86) vs 3.11% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
Triglycerides -0.44% (n=85) vs 9.56% (n=86) placebo @ 12wk30 mg
percent change · % of baseline
NCT06173570 · Phase 2
show 7 more results
-0.83% (n=85) vs 9.04% (n=86) placebo @ 12wk30 mg
NCT06173570 · Phase 2
1.93% (n=84) vs 9.56% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
1.72% (n=84) vs 9.04% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
2.9% (n=85) vs 9.56% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
2.17% (n=85) vs 9.04% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
3.06% (n=86) vs 9.56% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
2.81% (n=86) vs 9.04% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
Non-HDL-C -41.65% (n=85) vs 3.53% (n=86) placebo @ 12wk30 mg
percent change · % of baseline
NCT06173570 · Phase 2
show 7 more results
-41.35% (n=85) vs 2.86% (n=86) placebo @ 12wk30 mg
NCT06173570 · Phase 2
-35.13% (n=84) vs 3.53% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
-34.77% (n=84) vs 2.86% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
-29.86% (n=85) vs 3.53% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
-29.42% (n=85) vs 2.86% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
-26.85% (n=86) vs 3.53% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
-26.13% (n=86) vs 2.86% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
VLDL-C 0.46% (n=85) vs 7.19% (n=86) placebo @ 12wk30 mg
percent change · % of baseline
NCT06173570 · Phase 2
show 7 more results
0.42% (n=85) vs 6.74% (n=86) placebo @ 12wk30 mg
NCT06173570 · Phase 2
2.21% (n=84) vs 7.19% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
1.77% (n=84) vs 6.74% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
4.02% (n=85) vs 7.19% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
2.67% (n=85) vs 6.74% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
1.13% (n=86) vs 7.19% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
0.81% (n=86) vs 6.74% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
Apo A1 5.72% (n=85) vs 4.46% (n=86) placebo @ 12wk30 mg
percent change · % of baseline
NCT06173570 · Phase 2
show 7 more results
5.55% (n=85) vs 3.82% (n=86) placebo @ 12wk30 mg
NCT06173570 · Phase 2
3.61% (n=84) vs 4.46% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
3.79% (n=84) vs 3.82% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
3.25% (n=85) vs 4.46% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
2.89% (n=85) vs 3.82% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
1.67% (n=86) vs 4.46% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
2.52% (n=86) vs 3.82% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
Apo B -36.95% (n=85) vs 2.92% (n=86) placebo @ 12wk30 mg
percent change · % of baseline
NCT06173570 · Phase 2
show 7 more results
-36.86% (n=85) vs 2.44% (n=86) placebo @ 12wk30 mg
NCT06173570 · Phase 2
-34.33% (n=84) vs 2.92% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
-33.85% (n=84) vs 2.44% (n=86) placebo @ 12wk10 mg
NCT06173570 · Phase 2
-25.39% (n=85) vs 2.92% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
-24.53% (n=85) vs 2.44% (n=86) placebo @ 12wk3 mg
NCT06173570 · Phase 2
-24.08% (n=86) vs 2.92% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
-23.35% (n=86) vs 2.44% (n=86) placebo @ 12wk1 mg
NCT06173570 · Phase 2
Lp(a -19.43% (n=76) vs 0% (n=78) placebo @ 12wk30 mg
percent change · % of baseline
NCT06173570 · Phase 2
show 3 more results
-19.57% (n=81) vs 0% (n=78) placebo @ 12wk10 mg
NCT06173570 · Phase 2
-11.16% (n=75) vs 0% (n=78) placebo @ 12wk3 mg
NCT06173570 · Phase 2
-7.48% (n=75) vs 0% (n=78) placebo @ 12wk1 mg
NCT06173570 · Phase 2
Remnant Cholesterol -18.31% (n=77) vs -5% (n=80) placebo @ 12wk30 mg
percent change · % of baseline
NCT06173570 · Phase 2
show 3 more results
-22.95% (n=79) vs -5% (n=80) placebo @ 12wk10 mg
NCT06173570 · Phase 2
-8.33% (n=75) vs -5% (n=80) placebo @ 12wk3 mg
NCT06173570 · Phase 2
-9.09% (n=75) vs -5% (n=80) placebo @ 12wk1 mg
NCT06173570 · Phase 2

Recaticimab

LDL-C -45%450 mg Q12W
percent change · % of baseline
No placebo or comparator arm
NCT04849000 · Phase 3 · sponsor-reported, not registry data
show 2 more results
-52.8%300 mg Q8W
NCT04849000 · Phase 3 · sponsor-reported, not registry data
-49.6%150 mg Q4W
NCT04849000 · Phase 3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Laroprovstat's landscape · Recaticimab's landscape